ARTICLE | Top Story
PDL up after elotuzumab deal
August 20, 2008 10:58 PM UTC
PDL (NASDAQ:PDLI) gained $0.64 to $12.44 on Wednesday after announcing late Tuesday an agreement with Bristol-Myers (NYSE:BMY) to co-develop and commercialize PDL's elotuzumab (HuLuc63). The mAb again...